Business Context and Reporting Period
Iveda Solutions, Inc. (IVDA) filed a Form 8-K on April 15, 2025, announcing a non-reliance on previously issued financial statements. This action follows an SEC order on May 3, 2024, barring the company's former auditor, BF Borgers, from practicing before the Commission. Consequently, Iveda engaged Weinberg & Co to re-audit the fiscal year ended December 31, 2023, and audit the year ended December 31, 2024. The filing details restatements affecting financial periods from 2022 through the third quarter of 2024.
Key Financial Metrics and Restatement Impact
The filing does not provide current revenue figures but details significant adjustments to expenses, assets, and net losses. The restatements primarily involve the expensing of previously capitalized software development costs, corrections to deferred tax assets, and reclassifications of joint venture investments.
- Net Loss Adjustments (2023): Restated net losses increased significantly due to R&D expensing. For the nine months ended September 30, 2023, the net loss attributable to Iveda increased from $(2,136,453) to $(2,682,855).
- Net Loss Adjustments (2024): For the nine months ended September 30, 2024, the net loss attributable to Iveda increased from $(2,157,487) to $(2,470,014).
- Accumulated Deficit: As of September 30, 2024, the accumulated deficit was restated from $(50,099,282) to $(51,665,847).
- Asset Reductions: Property and Equipment and Intangible Assets were significantly reduced. For example, as of September 30, 2024, Intangible Assets were reduced by $1,131,962 to $0.
- Cash Flow: Operating cash flows were negatively adjusted. For the nine months ended September 30, 2024, net cash used in operating activities increased from $(3,203,769) to $(3,543,119).
Material Changes Versus Prior Periods
The material changes stem from accounting errors identified during the re-audit process:
- Deferred Tax Assets: A $146,560 deferred tax asset in the Taiwan subsidiary was deemed invalid and removed, increasing the accumulated deficit as of December 31, 2022.
- Intercompany Payables: An understatement of $200,000 in intercompany payables to Iveda Taiwan was corrected.
- R&D Capitalization: The company erroneously capitalized software development costs in 2023 and 2024. These costs were reclassified as expenses, increasing R&D expenses and net losses. Total adjustments for R&D expensing included $792,612 for 2023 activity and $339,350 for activity through September 30, 2024.
- Joint Venture Accounting: An $180,000 investment in Iveda Phils JV was reclassified from consolidation to the equity method, affecting cash, payables, and non-controlling interest.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, revenue outlook, or management commentary regarding future performance. The primary risk disclosed is the reliability of historical financial data. Investors are advised that previously issued financial statements for the year ended December 31, 2023, and the 2023 and 2024 quarterly reports should no longer be relied upon. The company is in the process of issuing restated financial statements in its Form 10-K filed coincident with this 8-K.
Key Facts for Investor Verification
- Auditor Change: Verify the independence and qualifications of the new auditor, Weinberg & Co (PCAOB ID #572).
- Restated 10-K: Review the full Form 10-K filed on April 15, 2025, specifically "Note 11 - Restatement of Previously Issued Financial Statements," for complete details on the restated balance sheets and income statements.
- Capitalization Policy: Confirm the company's new internal controls regarding the capitalization of software development costs to prevent recurrence.
- Liquidity Position: Assess the company's liquidity based on the restated cash balances (e.g., $3,596,278 as of September 30, 2024) and the increased operating cash burn.
- Stock Split: Note that per-share data reflects a 1-for-8 reverse stock split effected on September 17, 2024.